Advertisement
MDT vs TMO
Which Stock Would AI Choose? Medtronic (MDT) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Medtronic (MDT) has demonstrated accelerating revenue growth driven by its Pulse Field Ablation (PFA) franchise and the recent FDA approval of its HUGO robotic-assisted surgery system, yet the stock has pulled back roughly 25% from its November 2025 peak.
- Thermo Fisher Scientific (TMO) delivered $44.56 billion in full-year 2025 revenue with 4% growth, underpinned by a diversified life sciences and diagnostics portfolio, strategic M&A (mergers and acquisitions) activity, and a collaboration with OpenAI to integrate AI across its operations.
- MDT offers a compelling dividend profile with 48 consecutive years of payout increases and a yield near 3.5%, while TMO emphasizes capital deployment through acquisitions — committing $13 billion to M&A in 2025 alone.
- Both companies operate in the healthcare sector but serve fundamentally different market niches: MDT focuses on implantable medical devices and surgical robotics, while TMO is a dominant player in life sciences tools, bioprocessing, and clinical diagnostics.
- Recent sentiment has diverged — MDT's stock has struggled in 2026 despite operational improvements, while TMO has shown resilience with strong Q4 2025 results and positive forward guidance.
- From an AI-driven trend perspective, TMO's broader market exposure and steadier trajectory may currently present a more consistent pattern, while MDT's turnaround narrative introduces both opportunity and near-term volatility.
Introduction
For investors evaluating opportunities across the healthcare landscape, few comparisons capture the sector's breadth as effectively as Medtronic (MDT) versus Thermo Fisher Scientific (TMO). Though both are classified under the broad healthcare umbrella, they serve distinctly different ends of the value chain — MDT as a pure-play medical device manufacturer and TMO as a global leader in scientific instrumentation, laboratory services, and biopharmaceutical enablement. This comparison is particularly relevant for investors seeking to understand how two large-cap healthcare names with strong competitive moats perform in the current macroeconomic environment, where policy uncertainty, tariff dynamics, and divergent growth catalysts are shaping relative performance. Both seasoned traders and long-term investors may find this analysis useful when evaluating portfolio allocation between device-centered and science-services business models.
MDT Overview and Recent Performance
MDT, a Dublin-headquartered medical technology giant with a market capitalization of approximately $106.5 billion, has been navigating a notable transformation in recent quarters. The company's product portfolio spans cardiovascular devices, neuroscience technologies, medical-surgical products, and diabetes care — though the latter is now slated for a strategic spin-off. In recent market activity, MDT has experienced a visible divergence between operational performance and stock price behavior. The company posted strong fiscal 2026 second-quarter results, with revenue growing 6.6% year-over-year to $9 billion, beating analyst expectations. The standout performer has been the Cardiovascular division, which achieved growth exceeding 10% — its fastest pace in over a decade — driven by the Pulse Field Ablation (PFA) franchise, including the Sphere-9 and PulseSelect systems for treating atrial fibrillation.
Another significant catalyst has been the FDA's recent clearance of the HUGO robotic-assisted surgery (RAS) system for urologic procedures, positioning Medtronic to compete in the large and growing surgical robotics market. Additionally, the involvement of activist investor Elliott Investment Management — which led to the addition of new board members and a renewed focus on core assets — has reinforced the company's strategic pivot. Despite these positive operational signals, MDT's stock has declined approximately 12% year-to-date in 2026 and sits roughly 25% below its 52-week high of $106.33 reached in late November 2025. The stock currently trades near $83 with a price-to-earnings (P/E) ratio around 22 and a dividend yield of approximately 3.46%, supported by 48 consecutive years of dividend increases.
TMO Overview and Recent Performance
TMO, headquartered in Waltham, Massachusetts, is the world's largest provider of scientific instrumentation, reagents, consumables, and specialty diagnostics services. The company serves pharmaceutical, biotechnology, academic, and government clients through four principal segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Thermo Fisher's full-year 2025 results underscored its scale and operational consistency: revenue reached $44.56 billion, representing 4% growth over the prior year, while adjusted earnings per share (EPS) grew 5% to $22.87. The fourth quarter was particularly strong, with revenue climbing 7% to $12.21 billion and adjusted EPS rising 8% to $6.57.
Thermo Fisher's recent performance has been defined by aggressive and strategic capital deployment. In 2025, the company committed approximately $13 billion to M&A, including the acquisition of Solventum's Filtration and Separation business and Sanofi's sterile fill-finish facility in New Jersey, alongside a definitive agreement to acquire Clario, a clinical trial endpoint data solutions provider. The company also established a strategic collaboration with OpenAI to integrate artificial intelligence across its operations and product offerings. TMO enters 2026 with revenue guidance of $46.3 billion to $47.2 billion (4%–6% growth) and adjusted EPS guidance of $24.22 to $24.80 (6%–8% growth). The stock has demonstrated relative resilience in recent months, with the company's diversified end-market exposure — spanning biopharma, diagnostics, and academia — providing a buffer against sector-specific headwinds.
Trending AI Robots
For traders seeking to navigate the contrasting dynamics between stocks like MDT and TMO, algorithmic trading tools can offer a data-driven edge. Tickeron's Trending AI Robots page curates a select group of top-performing AI trading bots from a broader pool of hundreds of available systems. These bots are designed to trade thousands of different tickers, but only those demonstrating the strongest alignment with current market conditions earn placement in this featured section. The AI robots span a wide spectrum of trading styles — from swing trading to high-frequency strategies — and vary by timeframe, risk profile, and statistical track record. Some bots have achieved win rates exceeding 65%, while others specialize in capturing trends in specific sectors, including healthcare. Each bot's performance history, drawdown metrics, and trade frequency are transparently displayed, allowing users to assess suitability based on their individual goals. Exploring the Trending AI Robots section may help traders identify automated strategies tailored to today's evolving market landscape.
Head-to-Head Comparison
At a fundamental level, MDT and TMO represent two contrasting investment propositions within healthcare. MDT is a medical device manufacturer whose growth is tied to procedural volumes, new product adoption cycles, and regulatory milestones such as HUGO's commercial launch. Its revenue base of roughly $34–$35 billion annually is smaller and more concentrated in therapeutic device categories. TMO, by contrast, operates at roughly 30% larger scale with approximately $44.6 billion in annual revenue, and its business model is built around recurring consumables, laboratory services, and bioprocessing — areas that benefit from secular growth in biopharmaceutical research and development (R&D) irrespective of any single product cycle.
From a risk perspective, MDT carries greater exposure to single-product outcomes. The success of the PFA franchise and the HUGO robot ramp will heavily influence near-term performance, and the planned Diabetes spin-off introduces execution risk. TMO's risks are more macro-oriented — academic and government funding fluctuations, tariff-related margin pressure (particularly in its Analytical Instruments segment), and integration challenges associated with its acquisitive growth strategy. On the momentum front, MDT's fundamentals are accelerating but its stock price has been under pressure, potentially signaling a dislocation that value-oriented investors may find interesting. TMO's steadier operational cadence and forward guidance suggest a more predictable trajectory, which may appeal to investors prioritizing consistency over turnaround upside.
Dividend income represents another differentiator. MDT's 3.46% yield and 48-year growth streak offer a tangible return component that TMO, with a more modest dividend profile focused on M&A-driven capital deployment, does not match. For income-focused investors, this tilts the comparison meaningfully in MDT's favor. Conversely, TMO's aggressive buyback and acquisition strategy has historically supported stronger total shareholder returns through capital appreciation.
Tickeron AI Verdict
Based on observable trend patterns, relative stability, and catalyst visibility, Tickeron's AI-driven analytical framework would likely express a measured preference for TMO in the current market environment. Thermo Fisher's diversified revenue base, strong Q4 2025 momentum, clear 2026 guidance, and consistent capital deployment strategy offer a more statistically stable trend profile — a characteristic that AI models tend to favor when assessing risk-adjusted positioning. MDT's operational turnaround narrative is compelling, particularly with the PFA franchise firing on all cylinders and HUGO entering the U.S. market, but the stock's persistent underperformance relative to its fundamentals introduces a degree of uncertainty that may weigh on algorithmic confidence scores. It is important to note that this assessment reflects probabilistic modeling rather than definitive forecasting, and individual investor circumstances, time horizons, and risk tolerances will always shape the final decision-making calculus.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDT is a StrongBuy and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MDT’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- MDT’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MDT’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- MDT’s TA Score: 4 bullish, 5 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
MDT (@Medical/Nursing Services) experienced а +0.01% price change this week, while TMO (@Medical Specialties) price change was +6.72% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -5.78%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -21.89%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
MDT is expected to report earnings on Aug 25, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical/Nursing Services (-5.78% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| MDT | TMO | MDT / TMO | |
| Capitalization | 107B | 211B | 51% |
| EBITDA | 9.81B | 11.7B | 84% |
| Gain YTD | -11.882 | -1.736 | 685% |
| P/E Ratio | 22.31 | 30.58 | 73% |
| Revenue | 36.4B | 45.2B | 81% |
| Total Cash | 9.22B | 1.12B | 824% |
| Total Debt | 28B | 43.2B | 65% |
MDT | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 72 | 62 | |
PRICE GROWTH RATING 1..100 | 58 | 40 | |
P/E GROWTH RATING 1..100 | 63 | 37 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as TMO (12). This means that MDT’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as MDT (100). This means that TMO’s stock grew similarly to MDT’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as MDT (72). This means that TMO’s stock grew similarly to MDT’s over the last 12 months.
TMO's Price Growth Rating (40) in the Medical Specialties industry is in the same range as MDT (58). This means that TMO’s stock grew similarly to MDT’s over the last 12 months.
TMO's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as MDT (63). This means that TMO’s stock grew similarly to MDT’s over the last 12 months.
| MDT | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 59% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 64% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 46% | 2 days ago 61% |
| Advances ODDS (%) | 2 days ago 51% | 3 days ago 61% |
| Declines ODDS (%) | 4 days ago 57% | 5 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 37% | 2 days ago 59% |
Advertisement
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.